

An overview of our Company

NeoClone Biotechnology, LLC
1202 Ann Street, Madison, WI 53713
P 608.260.8190, F 608.260.8192
www.neoclone.com


December 2005

NeoClone Overview

- Patented process for development of mouse monoclonal antibodies (mAbs) using a retroviral technique that produces multiple mAbs in a short timeframe and at competitive costs per clone.
- Diploid mAb producing cell lines
- Over 280 customers in 25+ countries, 9+ FTEs
- Current research focus is on *in vitro* and human mAb development

NeoClone's business model

We excel in the development of monoclonal antibodies



- Projects are usually shared risk
- Customer owns the rights to the developed mAb producing cell lines

The success rate

- On a per project basis, there is a 90+% likelihood that we will produce a mAb (5-50mgs) that is useful in the end user's assay.
- 80+% of the time we will produce more than one mAb meeting the above criteria (usually at least 4).
- 90+% of the time the isotype is IgG class with IgG1 being the most predominant.
- Have successfully developed mAbs against murine targets, toxins, whole cells, mixed antigens.
- Data gathered from over 200 antigens, 50+ customers

Additional services

- **Project fast tracking** – depending on your needs, we can aggressively pursue mAb development and deliver initial mAbs for your evaluation in as little as 8 weeks from the initial immunization
- **Antigen development** – peptide or recombinant protein
- **Alternate immunization schedules** – for projects where traditional approaches are not appropriate
- **Antibody purification** – multiple techniques available
- **Long-term cell line storage** – in LN₂
- **mAb characterization** – affinity and/or specificity measurement
- **Additional ascites development** – up to 100 mice at a time